首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Quantitative approach to skin field cancerization using a nanoencapsulated photodynamic therapy agent: a pilot study
【24h】

Quantitative approach to skin field cancerization using a nanoencapsulated photodynamic therapy agent: a pilot study

机译:纳米胶囊光动力疗法治疗皮肤癌的定量方法:一项初步研究

获取原文
           

摘要

Background: This paper introduces a new nanoformulation of 5-aminolevulinic acid (nano-ALA) as well as a novel quantitative approach towards evaluating field cancerization for actinic keratosis and/or skin photodamage. In this pilot study, we evaluated field cancerization using nano-ALA and methyl aminolevulinate (MAL), the latter being commercialized as Metvix?.Methods and results: Photodynamic therapy was used for the treatment of patients with selected skin lesions, whereas the fluorescence of the corresponding photosensitizer was used to evaluate the time evolution of field cancerization in a quantitative way. Field cancerization was quantified using newly developed color image segmentation software. Using photodynamic therapy as the precancer skin treatment and the approach introduced herein for evaluation of fluorescent area, we found that the half-life of field cancerization reduction was 43.3 days and 34.3 days for nano-ALA and MAL, respectively. We also found that nano-ALA targeted about 45% more skin lesion areas than MAL. Further, we found the mean reduction in area of skin field cancerization was about 10% greater for nano-ALA than for MAL.Conclusion: Although preliminary, our findings indicate that the efficacy of nano-ALA in treating skin field cancerization is higher than that of MAL.
机译:背景:本文介绍了一种新的5-氨基乙酰丙酸(nano-ALA)的纳米制剂,以及一种新颖的定量方法来评估光化性角化病和/或皮肤光损伤的田间癌变。在这项初步研究中,我们使用纳米ALA和氨基乙酰丙酸甲酯(MAL)评估了现场癌变,后者以Metvix?的形式商业化。方法和结果:光动力疗法用于治疗某些皮肤病变的患者,而荧光相应的光敏剂用于定量评估田间癌变的时间演变。使用新开发的彩色图像分割软件对现场癌变进行了量化。使用光动力疗法作为癌前皮肤治疗和本文介绍的评估荧光面积的方法,我们发现,纳米ALA和MAL降低现场癌变的半衰期分别为43.3天和34.3天。我们还发现,纳米ALA比MAL靶向皮肤病变区域多约45%。此外,我们发现纳米ALA的皮肤癌变区域平均减少量比MAL大约大10%。结论:尽管是初步的,但我们的发现表明,纳米ALA在治疗皮肤癌变中的功效高于MAL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号